InMed Stock Today


USD 2.74  0.05  1.86%   

Market Performance
0 of 100
Odds Of Distress
Less than 38
InMed Pharmaceuticals is selling for 2.74 as of the 4th of December 2022. This is a 1.86 percent increase since the beginning of the trading day. The stock's lowest day price was 2.64. InMed Pharmaceuticals has about a 38 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for InMed Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 5th of September 2022 and ending today, the 4th of December 2022. Click here to learn more.
Fiscal Year End
IPO Date
12th of November 2020
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada. Inmed Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 1.09 M outstanding shares of which 9.2 K shares are currently shorted by investors with about 0.06 days to cover. More on InMed Pharmaceuticals

Moving against InMed Pharmaceuticals

-0.56MRNAModerna Potential GrowthPairCorr

InMed Pharmaceuticals Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. InMed Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding InMed Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
InMed Pharmaceuticals generated a negative expected return over the last 90 days
InMed Pharmaceuticals has high historical volatility and very poor performance
The company reported the last year's revenue of 1.09 M. Reported Net Loss for the year was (18.6 M) with profit before taxes, overhead, and interest of 543.55 K.
InMed Pharmaceuticals has about 9.35 M in cash with (15.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.98, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
InMed Pharmaceuticals has a frail financial position based on the latest SEC disclosures
Latest headline from MacroaxisInsider: InMed Pharmaceuticals exotic insider transaction detected
Average Analyst Recommendation
Analysts covering InMed Pharmaceuticals report their recommendations after researching InMed Pharmaceuticals' financial statements, talking to executives and customers, or listening in on InMed Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering InMed Pharmaceuticals. The InMed consensus assessment is calculated by taking the average forecast from all of the analysts covering InMed Pharmaceuticals.
Strong Buy2 Opinions
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of InMed Pharmaceuticals based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of InMed Pharmaceuticals financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares Diluted294.9 K309.1 K
Sufficiently Down
Slightly volatile
Weighted Average Shares294.9 K309.1 K
Sufficiently Down
Slightly volatile
Current Liabilities2.3 M2.5 M
Significantly Down
Slightly volatile
Total Liabilities2.5 M2.8 M
Significantly Down
Slightly volatile
Total Debt251.3 K242.8 K
Sufficiently Up
Slightly volatile
Current AssetsM7.5 M
Notably Up
Slightly volatile
Total Assets9.3 M8.8 M
Notably Up
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of InMed Pharmaceuticals' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Cautious HoldUndervalued
Financial Strength
InMed Pharmaceuticals' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to InMed Pharmaceuticals' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand InMed Pharmaceuticals' financial leverage. It provides some insight into what part of InMed Pharmaceuticals' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on InMed Pharmaceuticals' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how InMed Pharmaceuticals deploys its capital and how much of that capital is borrowed.
InMed Pharmaceuticals cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company has 698.5 K in debt with debt to equity (D/E) ratio of 0.06, which may show that the company is not taking advantage of profits from borrowing. InMed Pharmaceuticals has a current ratio of 3.45, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist InMed Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, InMed Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like InMed Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for InMed to invest in growth at high rates of return. When we think about InMed Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(9.51 Million)
InMed Pharmaceuticals (INM) is traded on NASDAQ Exchange in USA and employs 13 people. The company currently falls under 'Nano-Cap' category with total capitalization of 2.98 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate InMed Pharmaceuticals's market, we take the total number of its shares issued and multiply it by InMed Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. InMed Pharmaceuticals runs under Healthcare sector within Biotechnology industry. The entity has 1.09 M outstanding shares of which 9.2 K shares are currently shorted by investors with about 0.06 days to cover. InMed Pharmaceuticals has about 9.35 M in cash with (15.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.98, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check InMed Pharmaceuticals Probability Of Bankruptcy
Roughly 84.0 (percent) of InMed Pharmaceuticals outstanding shares are held by regular investors with 0.46 % owned by insiders and only 15.29099999999999 pct. by outside corporations.

Ownership Allocation (%)

Check InMed Ownership Details

InMed Stock Price Odds Analysis

Based on a normal probability distribution, the odds of InMed Pharmaceuticals jumping above the current price in 90 days from now is about 81.77%. The InMed Pharmaceuticals probability density function shows the probability of InMed Pharmaceuticals stock to fall within a particular range of prices over 90 days. Considering the 90-day investment horizon the stock has a beta coefficient of 2.1325. This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, InMed Pharmaceuticals will likely underperform. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. InMed Pharmaceuticals is significantly underperforming NYSE Composite.
  Odds Below 2.74HorizonTargetOdds Above 2.74
18.19%90 days
Based on a normal probability distribution, the odds of InMed Pharmaceuticals to move above the current price in 90 days from now is about 81.77 (This InMed Pharmaceuticals probability density function shows the probability of InMed Stock to fall within a particular range of prices over 90 days) .

InMed Stock Institutional Holders

Institutional Holdings refers to the ownership stake in InMed Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of InMed Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing InMed Pharmaceuticals' value.
InstituionSecurity TypeTotal SharesValue
Virtu Financial LlcCommon Shares11.3 K20 K
Ubs Group AgCommon Shares5.8 K38 K
View InMed Pharmaceuticals Diagnostics

InMed Pharmaceuticals Historical Income Statement

InMed Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting InMed's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of InMed Pharmaceuticals revenue and expense. InMed Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
InMed Pharmaceuticals Operating Expenses is relatively stable at the moment as compared to the past year. The company's current value of Operating Expenses is estimated at 11.54 Million. Research and Development Expense is expected to hike to about 6.4 M this year, although the value of Consolidated Income will most likely fall to (9.9 M). View More Fundamentals

InMed Stock Against Markets

Picking the right benchmark for InMed Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in InMed Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for InMed Pharmaceuticals is critical whether you are bullish or bearish towards InMed Pharmaceuticals at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in InMed Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run CEO Directory Now


CEO Directory

Screen CEOs from public companies around the world
All  Next Launch Module

InMed Pharmaceuticals Corporate Management

Elected by the shareholders, the InMed Pharmaceuticals' board of directors comprises two types of representatives: InMed Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of InMed. The board's role is to monitor InMed Pharmaceuticals' management team and ensure that shareholders' interests are well served. InMed Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, InMed Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Sazzad MSc - CoFounderProfile
MIB Chem - CEO PresProfile
Ado Muhammad - Consultant AffairsProfile
Colin Clancy - Director RelationsProfile
Eric Hsu - VP RDProfile
Jerry Griffin - VP MarketingProfile
Michael PEng - Chief OfficerProfile

Invested in InMed Pharmaceuticals?

The danger of trading InMed Pharmaceuticals is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of InMed Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than InMed Pharmaceuticals. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile InMed Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please see Risk vs Return Analysis. You can also try Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Complementary Tools for analysis

When running InMed Pharmaceuticals price analysis, check to measure InMed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy InMed Pharmaceuticals is operating at the current time. Most of InMed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of InMed Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move InMed Pharmaceuticals' price. Additionally, you may evaluate how the addition of InMed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Global Correlations
Find global opportunities by holding instruments from different markets
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
CEO Directory
Screen CEOs from public companies around the world
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Is InMed Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of InMed Pharmaceuticals. If investors know InMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about InMed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
Return On Assets
Return On Equity
The market value of InMed Pharmaceuticals is measured differently than its book value, which is the value of InMed that is recorded on the company's balance sheet. Investors also form their own opinion of InMed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is InMed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because InMed Pharmaceuticals' market value can be influenced by many factors that don't directly affect InMed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine InMed Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, InMed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.